id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1976-N-0520-0012,FDA,FDA-1976-N-0520,Certain Estrogen-Androgen Combination Drugs; Drugs for Human Use; Drug Efficacy Study Implementation; Amendment and Opportunity for Hearing,Notice,Notice of Opportunity of Hearing,2003-04-16T04:00:00Z,2003,4,,,2020-02-20T15:27:16Z,03-9065,0,0,090000648053be8e
FDA-1976-N-0520-0013,FDA,FDA-1976-N-0520,"Notice of Withdrawal, Pharmacia & Upjohn et al.; Withdrawal of Approval of One New Drug Application and Four Abbreviated New Drug Applications",Notice,Withdrawal,2003-04-16T04:00:00Z,2003,4,,,2018-08-02T15:25:33Z,03-9064,0,0,090000648053be8f
FDA-1976-N-0520-0015,FDA,FDA-1976-N-0520,Pharmacia & Upjohn et al.; Withdrawal of Approval of One New Drug Application and Four Abbreviated New Drug Applications,Notice,Withdrawal,2003-04-16T04:00:00Z,2003,4,,,2026-01-30T18:06:11Z,,0,0,090000648053be92
FDA-1976-N-0520-0014,FDA,FDA-1976-N-0520,Pharmacia & Upjohn et al.; Withdrawal of Approval of One New Drug Application and Four Abbreviated New Drug Applications,Notice,Withdrawal,2003-04-16T04:00:00Z,2003,4,,,2026-01-30T18:05:48Z,,0,0,090000648053be90